ICYMI, this week we had stories on physician assistants, diverse perspectives in aesthetic medicine, and more.
An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.
Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.
The Revolutionizing Atopic Dermatitis conference begins with presentations focused on new treatments, data, and more in atopic dermatitis.
Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.
Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research dives into the importance of the results from their recently released study.
Expert panelists discussed the pros, cons, and unknowns of the fast-growing roster of new AD treatments in a session at the 4th Annual Revolutionizing Atopic Dermatitis Conference held April 9 to 11, 2022 in Baltimore, Maryland.
Experts take a closer look at when to watch, and what to watch for in patients on JAK inhibitors.
An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.
An abstract presentation at the current Revolutionizing Atopic Dermatitis Conference highlighted using web-based education on AD for nursing students and RNs.
What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.
It's a hallmark of atopic dermatitis, but isn't always easy to assess. A presentation at the Revolutionizing Atopic Dermatitis meeting looks at available tools.
In her talk at the Revolutionizing Atopic Dermatitis Conference, Madison Cook, BS, gives tips on how to increase accountability, common barriers to overcome with patients, and more.
Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, explores the hidden burdens of itch that many pediatric patients and parents have to deal with on a daily basis. She expanded on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference was held from April 9 to 11 in Baltimore, Maryland.
A RAD conference abstract presentation highlights the demographic, prevalence, and comorbidity data for adults with atopic dermatitis.
Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment.
Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the importance of recognizing children with more severe atopic disease and a team approach to treatment.
What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.
Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, discusses the American Academy of Dermatology's approach to atopic dermatitis management.
While cigarette smoking has decreased in recent years, the use of e-cigarettes has only grown. But what are e-cigarettes associated risks for non-melanoma skin cancer? A recent study aims to find out.
Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research expands on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is held from April 9 to 11 in Baltimore, Maryland.
Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, talks about how education of patients is so important, the upcoming parts of the AAD guidelines to look forward to, and more.
The human microbiota and its involvement in human health and disease has been emphasized in recent years. Now, researchers have begun to explore whether a patient’s unique microbiota may influence skin cancer risk and response to therapy.
Dermatology Times® invites medical professionals in the dermatology community to speak out on the vital issues facing the specialty.
The education on how to treat patients with skin issues in this group needs to be expanded so physicians can better treat their patients.
In this month's Legal Eagle, David J. Goldberg, MD, JD, dives into a case of amount for fees charged for medical records.
In this week’s Pointers with Dr Portela, the 208SkinDoc highlights alopecia, discussing the different types, and the emotional impact of hair loss.
There is a theory that professional acne care can be effective not only in decreasing clinical signs but also in improving quality of life.
Now, with an increasing emphasis on multidisciplinary tumor review boards and heightened expectations for pipeline drugs, physicians have new tools for building treatment plans that may push response rates beyond the 30% range.
“Microneedling has been touted to the consumer as a means to enhance the penetration of moisturizers, vitamins, skin-lightening ingredients, and other cosmeceuticals. Is this enhanced penetration good? It depends.”
“With a traditional QRP [qualified retirement plan], a participant trades today’s tax rates on their contribution for the tax rates in the future, when they withdraw the money from the plan. If rates rise, the QRP might prove not to be a good deal at all.”
Dr Andrew Blauvelt discusses the relevance of dupilumab treatment response as seen in the LIBERTY AD OLE and LIBERTY AD CHRONOS studies and shares his approaches to improving atopic dermatitis management.
An expert dermatologist provides insight on unmet needs in clinical trial endpoint measurements that would improve the management of atopic dermatitis.
Andrew Blauvelt, MD, MBA, shares clinical pearls for the management of atopic dermatitis with systemic therapy.